- Home
- JPC vs ACAD Comparison
JPC vs ACAD Comparison
Compare JPC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- ACAD
- Stock Information
- Founded
- JPC 2003
- ACAD 1993
- Country
- JPC United States
- ACAD United States
- Employees
- JPC N/A
- ACAD N/A
- Industry
- JPC Investment Managers
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- ACAD Health Care
- Exchange
- JPC Nasdaq
- ACAD Nasdaq
- Market Cap
- JPC 2.6B
- ACAD 2.9B
- IPO Year
- JPC N/A
- ACAD 2004
- Fundamental
- Price
- JPC $8.01
- ACAD $17.50
- Analyst Decision
- JPC
- ACAD Buy
- Analyst Count
- JPC 0
- ACAD 19
- Target Price
- JPC N/A
- ACAD $26.44
- AVG Volume (30 Days)
- JPC 998.5K
- ACAD 1.5M
- Earning Date
- JPC 01-01-0001
- ACAD 11-06-2024
- Dividend Yield
- JPC 7.57%
- ACAD N/A
- EPS Growth
- JPC N/A
- ACAD N/A
- EPS
- JPC N/A
- ACAD 0.78
- Revenue
- JPC N/A
- ACAD $929,236,000.00
- Revenue This Year
- JPC N/A
- ACAD $37.34
- Revenue Next Year
- JPC N/A
- ACAD $7.25
- P/E Ratio
- JPC N/A
- ACAD $22.41
- Revenue Growth
- JPC N/A
- ACAD 47.06
- 52 Week Low
- JPC $5.94
- ACAD $14.15
- 52 Week High
- JPC $7.36
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- JPC 41.59
- ACAD 54.79
- Support Level
- JPC $7.98
- ACAD $16.78
- Resistance Level
- JPC $8.11
- ACAD $17.60
- Average True Range (ATR)
- JPC 0.05
- ACAD 0.68
- MACD
- JPC -0.01
- ACAD -0.03
- Stochastic Oscillator
- JPC 10.53
- ACAD 45.21
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.